US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

In Re: National Prescription Opiate Litigation

Track this case

Case overview

Case Number:

1:17-md-02804

See also:

Court:

Ohio Northern

Nature of Suit:

P.I.: Other

Multi Party Litigation:

Class Action, Multi-district Litigation

Judge:

Dan Aaron Polster (MDL 28

Firms

Companies

Government Agencies

Sectors & Industries:

  1. October 12, 2022

    Opioid Attys Stress 'Staggering' Costs In 6th Circ. Fee Feud

    Lead plaintiffs attorneys in multidistrict opioid litigation on Wednesday lambasted hundreds of local governments that are challenging a special fund for attorney fees, telling the Sixth Circuit that they've incurred "staggering" costs and that the challenge belongs in the dustbin.

  2. October 11, 2022

    Opioid Judge Won't Halt 'Waste Of Time' Ohio Trial

    A Cleveland federal judge overseeing thousands of lawsuits against drug companies said Tuesday that he would not halt trial preparations involving a southwestern Ohio county and several major pharmacy chains while the Sixth Circuit reviews the legal theory that led to a $650 million verdict in a similar case.

  3. October 07, 2022

    New Opioid Case Called 'Waste Of Time' Amid 6th Circ. Appeal

    The hugely expensive effort to prepare a new bellwether trial in multidistrict opioid litigation should cease because the Sixth Circuit might soon reject the controversial legal theory undergirding opioid cases, according to major pharmacy chains.

  4. October 05, 2022

    Opioid MDL's Verdict Watchdog Deserves DQ, Pharmacies Say

    The watchdog overseeing implementation of a verdict against CVS Pharmacy, Walgreens and Walmart in multidistrict opioid litigation has a conflict of interest because he's already a special master tasked with impartial dispute resolution in the MDL, the drugstore chains said on Wednesday.

  5. October 04, 2022

    Cherokees, Walmart Settle Opioid Fight Amid 10th Circ. Appeal

    The Cherokee Nation and Walmart have agreed to settle the tribe's suit over the retailer's alleged role in the opioid crisis, according to a notice filed Monday in Oklahoma state court.

  6. September 30, 2022

    Administrator Named In CVS-Walgreens-Walmart Opioid Order

    A Cleveland federal judge presiding over thousands of opioid cases appointed his special master on Friday as administrator for abatement programs mandated as part of a judgment against CVS, Walgreens and Walmart, which were found liable to the tune of $650 million for contributing to prescription painkiller-related problems in two Ohio counties.

  7. September 21, 2022

    Opioid MDL Attys To Get 'Much More Aggressive' As Talks Lag

    Months of talks with drug companies poised to become the next big targets in multidistrict opioid litigation haven't yielded major progress, and a "much more aggressive" approach is needed, one of the highest-ranking attorneys for MDL plaintiffs said Wednesday.

  8. September 07, 2022

    CVS, Walgreens, Walmart Will Fight $650M Ohio Opioid Order

    Three major pharmacy chains plan to challenge a federal judge's order to pay more than $650 million toward a plan to abate the opioid epidemic in two Northeast Ohio counties, according to notices of appeal filed Wednesday.

  9. September 06, 2022

    Pharmacies Flooded NM With Opioids, AG Says As Trial Starts

    New Mexico's attorney general launched an opioid-crisis trial on Tuesday against three pharmacy giants with a comparison of stewardship of drugs to that of water in his arid state, saying reckless opioid dispensing by Walgreens, Walmart and Kroger "smashed those dams wide open."

  10. September 02, 2022

    The Hottest Topics For Health Attys In 2022's Homestretch

    A torrid 2022 for health care litigation is entering a red-hot homestretch featuring fallout from the U.S. Supreme Court's explosive repudiation of abortion rights, the potential for three False Claims Act clashes at the high court, and the increasingly likely prospect of a funding fiasco for the U.S. Food and Drug Administration.